<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362196">
  <stage>Registered</stage>
  <submitdate>23/04/2012</submitdate>
  <approvaldate>23/04/2012</approvaldate>
  <actrnumber>ACTRN12612000453886</actrnumber>
  <trial_identification>
    <studytitle>Standard Issue Transfusion versus fresher red blood cell use in intensive care  - a randomized controlled trial</studytitle>
    <scientifictitle>The effect of transfusion of fresher blood versus standard care on  28 and 90 day mortality in patients admitted to ICU.</scientifictitle>
    <utrn />
    <trialacronym>TRANSFUSE</trialacronym>
    <secondaryid>ClinicalTrials.gov NCT01638416</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Blood transfusion</healthcondition>
    <healthcondition>Critically ill patients</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Anaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Experimental: These patients will receive the freshest available group-specific compatible RBC unit in the transfusion service.
Indication,timing and number of RBC units will be determined as per standard practice by the clinician for each individual situation.</interventions>
    <comparator>No intervention: standard of care. These patients will receive standard practice, which is the oldest available group-specific compatible RBC unit in the transfusion service.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>This study aims to determine whether, compared to standard care, transfusion of the freshest available allogeneic RBC decreases mortality of patients admitted to ICU.</outcome>
      <timepoint>90 day mortality</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Persistant Organ Dysfunction combined with death at day 28 defined as number of days requiring mechanical ventilation, renal replacement therapy and catecholamines.</outcome>
      <timepoint>day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mortality</outcome>
      <timepoint>Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Days alive and free of mechanical ventilation (post randomisation) at day 28</outcome>
      <timepoint>Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Days alive and free of RRT post randomisation at day 28</outcome>
      <timepoint>Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood stream infection rate in ICU post randomisation</outcome>
      <timepoint>While in ICU</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Length of stay in ICU post randomisation</outcome>
      <timepoint>At ICU discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients who suffer at least one febrile non-haemolytic transfusion reaction in ICU</outcome>
      <timepoint>While in ICU</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life (EQ5D) at 180 days</outcome>
      <timepoint>Day 180</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Length of stay in hospital post randomisation</outcome>
      <timepoint>At hospital discharge</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients hospitalised in ICU with an anticipated ICU stay of at least 24 hours, in whom the decision has been made by medical staff to transfuse at least one RBC unit.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Age younger than 18

A previous RBC transfusion during the current hospital admission (including transfusion in another hospital for transferred patients) 

Diagnosis of transplantation or hematologic diseases 

Pregnancy

Cardiac surgery during the present hospital admission 

Expected to die imminently (&lt;24hrs) 

The treating physician believes it is not in the best interest of the patient to be randomised in this trial.

Known objection to the administration of human blood products

Participation in a competing study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The inclusion exclusion criteria will be checked when a clinical decision is made to transfuse. Transfusion indication, timing and number of the RBC units will be determined by the treating clinicians.

Randomisation will be performed using a web based computer system.
The patient will be allocated a unique study identification number at randomisation (to identify their study involvement for the first and each subsequent RBC transfusion during their ICU stay. This number will be recorded on a sticker placed in the patientâ€™s chart and also on the RBC request form sent to the hospital transfusion service.</concealment>
    <sequence>The treatment allocation will be determined using variable block randomisation in a 1:1 ratio, stratified by centre</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>The study sample of 5000 patients will provide 90% power for a two-sided difference of 4.2% in the primary outcome of 90-day mortality between treatment groups. The baseline
mortality was estimated from a previous observational study. Patients in our study who would have been eligible for the TRANSFUSE trial had a hospital mortality of 25%. We conservatively estimate the 90-day mortality to be 28%. The sample size calculation was based on a 15% relative decrease in 90-day mortality, or an absolute decrease of 4.2% from 28% to 23.8%. With a type I error of 0.05 and a type II error of 0.1 (power 90%), the needed patient number is 2332 per group. According to previous studies, the loss to follow-up should not exceed 5%; the addition of 5% yields an accurate number of 4898 patients, which we have rounded up to 5000 patients. All analyses will be on an intention-to-treat basis, except where otherwise indicated. No imputation for missing data will be performed and the number of analysed observations will be reported. The level of significance is set to 0.05 in all analyses and P will not be adjusted for multiplicity. All analyses will be unadjusted unless otherwise specified. (See detailed description in TRANSFUSE SAP 2014 Kaukonen, Crit Care Resusc)</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/10/2012</anticipatedstartdate>
    <actualstartdate>14/11/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/12/2016</actualenddate>
    <samplesize>5000</samplesize>
    <actualsamplesize>4994</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,TAS,WA,VIC</recruitmentstate>
    <postcode>2640</postcode>
    <postcode>3004</postcode>
    <postcode>3084</postcode>
    <postcode>3350</postcode>
    <postcode>3550</postcode>
    <postcode>2148</postcode>
    <postcode>3128</postcode>
    <postcode>3144</postcode>
    <postcode>4870</postcode>
    <postcode>2298</postcode>
    <postcode>2617</postcode>
    <postcode>5000</postcode>
    <postcode>2605</postcode>
    <postcode>2139</postcode>
    <postcode>3175</postcode>
    <postcode>5043</postcode>
    <postcode>6959</postcode>
    <postcode>3220</postcode>
    <postcode>4215</postcode>
    <postcode>2250</postcode>
    <postcode>2305</postcode>
    <postcode>7250</postcode>
    <postcode>2170</postcode>
    <postcode>5112</postcode>
    <postcode>3135</postcode>
    <postcode>4101</postcode>
    <postcode>3168</postcode>
    <postcode>2750</postcode>
    <postcode>3076</postcode>
    <postcode>2031</postcode>
    <postcode>4102</postcode>
    <postcode>5011</postcode>
    <postcode>4029</postcode>
    <postcode>7000</postcode>
    <postcode>3050</postcode>
    <postcode>2065</postcode>
    <postcode>6000</postcode>
    <postcode>2217</postcode>
    <postcode>3065</postcode>
    <postcode>2010</postcode>
    <postcode>4350</postcode>
    <postcode>3011</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>South  Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>North Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Galway</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Cork</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Limerick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>St James</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state>Riyadh</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Monash University</primarysponsorname>
    <primarysponsoraddress>School of Public Health &amp; Preventive Medicine
Monash University
Level 3
553 St Kilda Road, Melbourne VIC 3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health Medical Research Council</fundingname>
      <fundingaddress>Level 1
16 Marcus Clarke Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Board of Ireland</fundingname>
      <fundingaddress>Grattan House, 67-72 Lower Mount Street, Grand Canal Dock, Dublin 2, Ireland</fundingaddress>
      <fundingcountry>Ireland</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council of New Zealand</fundingname>
      <fundingaddress>Level 3, 110 Stanley St, Grafton, Auckland 1010, New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Australian Red Cross Blood Service</fundingname>
      <fundingaddress>Optus Centre, 1/367 Collins St, Melbourne VIC 3000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University College Dublin</sponsorname>
      <sponsoraddress>Stillorgan Rd, Belfield, Dublin 4, Ireland</sponsoraddress>
      <sponsorcountry>Ireland</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>Australian Red Cross Blood Service</othercollaboratorname>
      <othercollaboratoraddress>Optus Centre, 1/367 Collins St, Melbourne VIC 3000</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>Finnish Red Cross Blood Service</othercollaboratorname>
      <othercollaboratoraddress>Kivihaantie 7, 00310 Helsinki, Finland</othercollaboratoraddress>
      <othercollaboratorcountry>Finland</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>New Zealand Blood Service</othercollaboratorname>
      <othercollaboratoraddress>11 Great South Rd, Epsom, Auckland 1050, New Zealand</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>Irish Blood Transfusion Service</othercollaboratorname>
      <othercollaboratoraddress>5 D'Olier Street, Dublin, Ireland</othercollaboratoraddress>
      <othercollaboratorcountry>Ireland</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>King Abdulaziz Medical City blood bank</othercollaboratorname>
      <othercollaboratoraddress>Ar Rimayah, 2682, Riyadh 14611, Saudi Arabia</othercollaboratoraddress>
      <othercollaboratorcountry>Saudi Arabia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>University College Dublin</othercollaboratorname>
      <othercollaboratoraddress>Stillorgan Road, Belfield campus, Dublin 4</othercollaboratoraddress>
      <othercollaboratorcountry>Ireland</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Red blood cell (RBC) transfusion is a very common and potentially life-saving treatment in intensive care units (ICUs). However, RBC transfusion has also been associated with an increased risk of morbidity and/or mortality in critically ill, surgical and trauma patients. Although this association is multifactorial, attention has increasingly focused on the possible adverse impact of transfusing RBC which have been stored for a prolonged time.The primary aim of the trial is to determine if transfusion of the freshest available RBC in critically ill patients compared to standard care decreases patient mortality.</summary>
    <trialwebsite>http://www.anzicrc.monash.org/transfuse-rct.html</trialwebsite>
    <publication>Crit Care Resusc. 2014 Dec;16(4):255-61.. A randomised controlled trial of standard transfusion versus fresher red blood cell use in intensive care (TRANSFUSE): protocol and statistical analysis plan. Kaukonen KM, Bailey M, Ady B, Aubron C, French C, Gantner D, Irving D, Murray L, Nichol A, PettilÃ¤ V, McQuilten Z, Cooper DJ.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress>55 Commercial Road
Ground Floor, Linay Pavilion
Melbourne VIC 3004
PO Box 315 Prahran
VIC 3181 Australia</ethicaddress>
      <ethicapprovaldate>23/04/2012</ethicapprovaldate>
      <hrec>81/12</hrec>
      <ethicsubmitdate>22/03/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Ms</title>
      <name>Bridget Ady</name>
      <address>ANZIC-RC
Monash University
Level 3
553 St Kilda Road
MELBOURNE VIC 3004
AUSTRALIA</address>
      <phone>+61 3 99030035</phone>
      <fax>+61 3 99030071</fax>
      <email>bridget.ady@monash.edu</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Bridget Ady</name>
      <address>ANZIC-RC
Monash University
Level 3
553 St Kilda Road
MELBOURNE VIC 3004
AUSTRALIA</address>
      <phone>+61 3 99030035</phone>
      <fax>+61 3 99030071</fax>
      <email>bridget.ady@monash.edu</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Bridget Ady</name>
      <address>ANZIC-RC
Monash University
Level 3
553 St Kilda Road
MELBOURNE VIC 3004
AUSTRALIA</address>
      <phone>+61 3 99030035</phone>
      <fax>+61 3 99030071</fax>
      <email>bridget.ady@monash.edu</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>D. James Cooper AO</name>
      <address>ANZIC-RC
Monash University
Level 3
553 St Kilda Road
MELBOURNE VIC 3004
AUSTRALIA</address>
      <phone>+61 (0) 3 9903 0343</phone>
      <fax />
      <email>jamie.cooper@monash.edu</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>